Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)

• Published in: Nuclear medicine Vol. 43; no. 4; p. 115
• Main Authors: Dietlein, M, Dressler, J, Farahati, J, Grünwald, F, Leisner, B, Moser, E, Reiners, C, Schicha, H, Schober, O
• Format: Journal Article
• Language: English; German
• Published: Germany 01-08-2004
• Subjects: Contraindications; Germany; Humans; Iodine Radioisotopes - therapeutic use; Quality Assurance, Health Care; Radionuclide Imaging; Radiotherapy - standards; Thyroid Neoplasms - diagnostic imaging; Thyroid Neoplasms - radiotherapy
• ISSN: 0029-5566
• DOI: 10.1055/s-0038-1625313

The procedure guidelines for radioiodine therapy (RIT) of differentiated thyroid cancer (version 2) are the counter-part to the procedure guidelines for (131)I whole-body scintigraphy (version 2) and specify the interdisciplinary guidelines for thyroid cancer of the Deutsche Krebsgesellschaft and the Deutsche Gesellschaft für Chirurgie concerning the nuclear medicine part. Compared with version 1 facultative options for RIT can be chosen in special cases: ablative RIT for papillary microcarcinoma </=1 cm, ablative RIT for mixed forms of anaplastic and differentiated thyroid cancer, and RIT in patients with a measurable or increasing thyroglobulin concentration but without detectable metastases by imaging. The description of the pretherapeutic dosimetry now includes the isotopes (123)I and (124)I as well as a broader range of the activity of (131)I. Activities of 2-5 GBq (131)I are recommended for the first ablative RIT. If high accumulative activities of (131)I are expected, men who have not yet finished their family planning should be advised to the option of sperm cryoconservation. An interdisciplinary consensus is necessary whether the new TNM-classification (UICC, 6(th) edition, 2002) will lead to modified recommendations for surgical or nuclear medicine therapy, especially for the surgical completeness and for the ablative RIT of pT1 papillary cancer.